SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that cannabis rescheduling could be on the horizon following reports of potential executive action. The community is actively discussing the implications of this policy change, particularly how it might trigger a short squeeze and impact the broader cannabis sector. Some are also pointing to Tilray's 'Liquid Diamond' vapes as a potential catalyst.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its cultural significance within the cannabis space and its positioning as a "culture coin" on the Solana network. Discussions also highlight potential synergies with broader cannabis reform and related stocks like $TLRY, with community members emphasizing the project's long-term vision.

Aventus Network

Aventus Network ($AVT) is trending as traders discuss a potential breakout, Polkadot integration, and recent strategic advisory appointment in the UAE. Bullish traders are highlighting its oversold conditions and low market cap as catalysts for a potential rally. Community members are closely monitoring volume and potential new exchange listings.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending after its earnings report triggered a volatile swing, initially rising on strong AI chip sales and guidance, but then sharply declining during the earnings call. Community discussion revolves around potential profit-taking, concerns about non-AI revenue, and the impact of comments made during the call. Despite strong fundamentals, the stock's reaction highlights the market's sensitivity to AI-related news and broader sector trends.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is trending amid growing community enthusiasm and strong bullish sentiment, with some drawing comparisons to previous meme coin successes. The community is rallying behind $YEE's potential as an ERC-20 token on Ethereum, emphasizing its momentum and strong fundamentals. Some community members believe $YEE could become a leading narrative in the crypto space.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending as investors weigh its potential amid healthcare sector rotation and anticipation of a dividend payout. Technical analysts point to a possible breakout above the $340 resistance, while some community members speculate on news regarding ACA subsidies and potential DOJ developments as catalysts for a significant move. Despite some bearish sentiment, many see UNH as a long-term hold due to its leadership in the healthcare industry.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors digest better-than-expected earnings and revenue, alongside news of the CEO's upcoming departure which some see as a potential catalyst for innovation. Community discussions revolve around the company's guidance, share buybacks, and the potential for analyst upgrades. Bullish sentiment seems to be building on the prospect of new leadership and continued growth, particularly in the international market.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a potential bidding war with Paramount for Warner Bros. Discovery, with some investors hoping Netflix will abandon the deal and collect a $2.8 billion breakup fee, potentially boosting the stock; community chatter revolves around the deal's implications, regulatory hurdles, and potential impact on Netflix's financials and content strategy.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending amid discussions around its recent earnings, where the company beat EPS estimates but missed on revenue, leading to mixed reactions from investors. Community members are debating whether the stock's high PE ratio is justified, while others are focused on membership growth and digital sales. Some are speculating about a potential special dividend or stock split to attract more investors.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as traders eye whale short-covering behavior and potential institutional adoption. Community members are discussing potential partnerships and staking opportunities, as well as meme coins built on the Solana network. Some traders are calling for a breakout, while others express concerns about recent market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mural Oncology (NASDAQ:MURA) Insider Sells $10,474.88 in Stock

Mural Oncology PLC (NASDAQ:MURA - Get Free Report) insider Vicki Goodman sold 5,036 shares of Mural Oncology stock in a transaction that occurred on Monday, November 10th. The stock was sold at an...

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive agreement under which a unit of XOMA will acquire Mural for cash.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.muraloncology.com/news-releases/news-release-details/mural-oncology-announces-entry-agreement-be-acquired-xra-5-corp">deal</a>, each Mural Shareholder would receive a cash price of between $2.035 and $2.24 per share. The base cash price represents a premium of approximately 13.1% to Mural’s closing share price of $1.80 on Tuesday. The additional price per share of up to $0.205 will be paid if Mural’s closing net cash exceeds estimates.MURA stock jumped 14% in the premarket session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MURA">Mural</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/XOMA">XOMA</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.Mural's board of directors said that they have determined the acquisition and cash offer by XOMA, a biotechnology royalty aggregator, is in the best interest of all Mural shareholders. The board approved the acquisition and recommended that Mural shareholders vote in favor.The acquisition will be subject to the satisfaction of closing conditions, including approval by Mural shareholders. Excluding additional price per share, the deal values Mural at about $36.2 million.Mural Oncology announced plans to explore strategic alternatives in April after discontinuing all clinical development of Nemvaleukin. The decision followed data from a late-stage trial where Nemvaleukin in combination with Pembrolizumab did not achieve the primary endpoint of a statistically significant improvement in overall survival versus chemotherapy in platinum-resistant ovarian cancer. The company also saw no positive results from a mid-stage study of the drug in mucosal and cutaneous melanoma.MURA stock is down by 44% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Mural Oncology To Be Acquired By XOMA Royalty

The Mural board of directors said that they have determined the acquisition and cash offer by XOMA is in the best interest of all its shareholders. 

Equity

Mural Oncology Plc.'s stock (MURA) notched its best session ever on Tuesday, soaring nearly 134%, and extended gains in after-hours trading as the biotech firm said it was exploring strategic alternatives.The cancer drug maker said it would discontinue all clinical development of its lead drug candidate, nemvaleukin alfa, following disappointing data from two Phase 2 trials in melanoma and previously reported Phase 3 results in ovarian cancer.The company also said it had failed to meet the primary endpoint in its ARTISTRY-6 mucosal melanoma study, and preliminary data from a cutaneous melanoma cohort showed insufficient activity to continue.Mural said it plans to explore strategic alternatives, including a potential sale, merger, or other transaction, and has hired Lucid Capital Markets as its financial advisor.&nbsp;It has not received any offers or is in active discussions.&nbsp;As of Dec. 31, 2024, the company held about $144.4 million in cash and equivalents and will cut approximately 90% of its workforce as part of the strategic shift.The news sent message volume involving Mural Oncology on Stocktwits soaring by 62,000%, the highest among healthcare stocks, although sentiment plunged further into 'extremely bearish' territory.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/MURA_sentiment_and_message_volume_as_of_April_15_png_97c55d5bff.webp" alt="MURA sentiment and message volume as of April 15.png" width="1318" height="316"><figcaption>MURA sentiment and message volume as of April 15. | source: Stocktwits</figcaption></figure>Several skeptical retail watchers expect the stock to drop below $2 on Wednesday.<stembedurl>https://stocktwits.com/Smehran99/message/611776249</stembedurl><stembedurl>https://stocktwits.com/WMWilson/message/611761469</stembedurl>According to Koyfin, four analysts cover the stock, with two recommending a 'strong buy' and two with a 'hold' rating.Mural Oncology's stock has lost over a quarter of its valuation this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives

The company will cut approximately 90% of its workforce as part of the strategic shift.

Mural Oncology is an independent public company. Mural Oncology would focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa and the company's portfolio of novel, preclinical engineered cytokines, comprised of tumor-targeted split interleukin-12 (IL-12) and interleukin-18 (IL-18).

Mural Oncology plc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$2.04
Prev Close	$2.04
Open	$2.03
Dividend Yield	0.00%
50-Day Moving Average	$2.08
Beta	0.00
Avg. Volume	206,162.74
PE Ratio	-0.29

52-Week High	$4.74
52-Week Low	$0.95
Market Capitalization	$35.38M
EPS (Annual)	-$7.58
Price to Book	0.64
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MURA
Mural Oncology plc

Feed

News

Sentiment

Fundamentals

Info

Latest MURA News

MURAMural Oncology plc